Page last updated: 2024-09-03

imatinib mesylate and Hypomelanosis

imatinib mesylate has been researched along with Hypomelanosis in 15 studies

Research

Studies (15)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	8 (53.33)	29.6817
2010's	6 (40.00)	24.3611
2020's	1 (6.67)	2.80

Authors

Authors	Studies
Daudén, E; García-Diez, A; Llamas-Velasco, M; Ovejero-Merino, E; Requena, L; Steegmann, JL	1
Chen, Q; Chua, SH; Kok, WL; Lee, SSJ; Ng, SK	1
Dogra, S; Handa, S; Khadwal, A; Kumari, S; Lad, D; Malhotra, P; Prakash, G; Suri, V; Varma, S; Vinay, K; Yanamandra, U	1
Chua, SH; Kok, WL	1
Fraga, J; García-Diez, A; Kutzner, H; Llamas-Velasco, M; Requena, L; Steegmann, JL	1
Han, H; Wang, YH; Yu, YY	1
Aleem, A	1
Bakhshi, S; Gupta, R; Kumar, L; Kumar, R; Medhi, K; Raina, V; Sharma, A	1
Abruzzese, E; Basciani, S; Fiore, D; Gnessi, L; Mariani, S; Persichetti, A; Spera, G; Watanabe, M	1
Dawkins, F; Dinh, K; Hasan, S; Kark, J; Lombardo, F	1
Cortes, J; Kantarjian, H; O'Brien, S; Talpaz, M; Tsao, AS	1
Grossman, WJ; Wilson, DB	1
Goh, AS; Lee, TC; Leong, KW	1
Bhatia, K; Doval, DC; Talwar, V	1
Ben-Bassat, I; Goldman, JM; Raanani, P	1

Trials

1 trial(s) available for imatinib mesylate and Hypomelanosis

Article	Year
Response assessment of patients with chronic myeloid leukemia receiving imatinib mesylate (Glivec) therapy: experience from a single center in a developing country. Leukemia & lymphoma, 2010, Volume: 51, Issue:10 Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Child; Female; Follow-Up Studies; Humans; Hyperpigmentation; Hypopigmentation; Imatinib Mesylate; India; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neutropenia; Piperazines; Pyrimidines; Thrombocytopenia; Treatment Outcome; Young Adult	2010

Article

Year

Response assessment of patients with chronic myeloid leukemia receiving imatinib mesylate (Glivec) therapy: experience from a single center in a developing country.

Leukemia & lymphoma, 2010, Volume: 51, Issue:10

Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Child; Female; Follow-Up Studies; Humans; Hyperpigmentation; Hypopigmentation; Imatinib Mesylate; India; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neutropenia; Piperazines; Pyrimidines; Thrombocytopenia; Treatment Outcome; Young Adult

2010

Other Studies

14 other study(ies) available for imatinib mesylate and Hypomelanosis

Article	Year
Cutaneous side effects in a cohort of patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: General description and further characterization, correlation with photoexposition and study of hypopigmentation as treatment's prognosti Dermatologic therapy, 2020, Volume: 33, Issue:6 Topics: Humans; Hypopigmentation; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Prognosis; Protein Kinase Inhibitors	2020
A case series of imatinib-induced generalized hypopigmentation and progression of existing acquired dermal melanocytosis. The Journal of dermatological treatment, 2017, Volume: 28, Issue:8 Topics: Aged; Antineoplastic Agents; Disease Progression; Female; Humans; Hypopigmentation; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Skin	2017
Long-term mucocutaneous adverse effects of imatinib in Indian chronic myeloid leukemia patients. International journal of dermatology, 2018, Volume: 57, Issue:3 Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Agents; Cross-Sectional Studies; Drug Eruptions; Edema; Eye Diseases; Female; Humans; Hyperpigmentation; Hypopigmentation; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lichenoid Eruptions; Male; Middle Aged; Mouth Diseases; Mouth Mucosa; Nail Diseases; Sex Factors; Skin Diseases, Vesiculobullous; Time Factors; Young Adult	2018
Picosecond 755-nm Alexandrite Lasers Are an Effective Treatment for Imatinib-Induced Hyperpigmentation. Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.], 2019, Volume: 45, Issue:4 Topics: Humans; Hyperpigmentation; Hypopigmentation; Imatinib Mesylate; Lasers, Solid-State; Treatment Outcome	2019
Hypopigmented macules secondary to imatinib for the treatment of chronic myeloid leukemia: a histopathologic and immunohistochemical study. Journal of cutaneous pathology, 2014, Volume: 41, Issue:5 Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Female; Humans; Hypopigmentation; Imatinib Mesylate; Immunohistochemistry; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Melanins; Melanocytes; Middle Aged; Piperazines; Pyrimidines; Skin Pigmentation	2014
Imatinib mesylate-induced repigmentation of vitiligo lesions in a patient with recurrent gastrointestinal stromal tumors. Journal of the American Academy of Dermatology, 2008, Volume: 59, Issue:5 Suppl Topics: Aged; Benzamides; Gastrointestinal Stromal Tumors; Humans; Hypopigmentation; Imatinib Mesylate; Male; Melanins; Neoplasm Recurrence, Local; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Vitiligo	2008
Hypopigmentation of the skin due to imatinib mesylate in patients with chronic myeloid leukemia. Hematology/oncology and stem cell therapy, 2009, Volume: 2, Issue:2 Topics: Adolescent; Adult; Antineoplastic Agents; Benzamides; Female; Follow-Up Studies; Humans; Hypopigmentation; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Skin Pigmentation; Treatment Outcome; Young Adult	2009
Reversible hair depigmentation in a patient treated with imatinib. Leukemia research, 2011, Volume: 35, Issue:6 Topics: Antineoplastic Agents; Benzamides; Hair Color; Hair Diseases; Humans; Hypopigmentation; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Middle Aged; Piperazines; Pyrimidines	2011
Hypopigmentation in an African patient treated with imatinib mesylate: a case report. Journal of the National Medical Association, 2003, Volume: 95, Issue:8 Topics: Aged; Benzamides; Biopsy, Needle; Black People; Follow-Up Studies; Hand; Humans; Hypopigmentation; Imatinib Mesylate; Male; Neoplasm Staging; Palliative Care; Piperazines; Pyrimidines; Risk Assessment; Stomach Neoplasms	2003
Imatinib mesylate causes hypopigmentation in the skin. Cancer, 2003, Dec-01, Volume: 98, Issue:11 Topics: Adult; Aged; Benzamides; Enzyme Inhibitors; Female; Humans; Hypopigmentation; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mitogen-Activated Protein Kinase Kinases; Phosphorylation; Piperazines; Promoter Regions, Genetic; Proto-Oncogene Proteins c-kit; Pyrimidines	2003
Hypopigmentation from imatinib mesylate (Gleevec). Journal of pediatric hematology/oncology, 2004, Volume: 26, Issue:3 Topics: Antineoplastic Agents; Benzamides; Black People; Child; Cord Blood Stem Cell Transplantation; Humans; Hypopigmentation; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Missouri; Piperazines; Pyrimidines	2004
Imatinib mesylate causes hypopigmentation in the skin. Cancer, 2004, Jun-01, Volume: 100, Issue:11 Topics: Benzamides; Enzyme Inhibitors; Humans; Hypopigmentation; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mitogen-Activated Protein Kinase Kinases; Phosphorylation; Piperazines; Protein-Tyrosine Kinases; Pyrimidines	2004
Imatinib mesylate induced skin hypopigmentation. The Journal of the Association of Physicians of India, 2007, Volume: 55 Topics: Antineoplastic Agents; Benzamides; Genes, abl; Humans; Hypopigmentation; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Skin Diseases	2007
Challenges in oncology. Case 3. Depigmentation in a chronic myeloid leukemia patient treated with STI-571. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Feb-01, Volume: 20, Issue:3 Topics: Antineoplastic Agents; Benzamides; Humans; Hypopigmentation; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines	2002